Scientists in Germany say they've been able to create a nasal vaccine that can stop the Covid-19 virus from multiplying in the nose and throat.
In animal studies, two doses of the vaccine blocked the virus from replicating in the upper airways, producing "sterilizing immunity" and preventing illness. The researchers claim that this is a significant breakthrough as it aims to prevent Covid-19 before it can cause infection.
The German vaccine takes a new approach by weakening the coronavirus through genetic modification, making it easier for the immune system to recognize and fight it off.
While several nasal vaccines are already in use or nearing completion of clinical trials, more work needs to be done before they can be widely used.
In China and India, nasal vaccines have been rolled out but their effectiveness is still unknown due to a lack of published studies.
The US is struggling with Covid-19, with hundreds of Americans dying daily from the infection. The development of next-generation Covid-19 vaccines that induce mucosal immunity and are long-lived is crucial in halting this progress.
Research suggests that boosting mucosal immunity can prevent Covid-19 before it starts to cause illness. This approach mimics the way firefighters would respond to a fire, quickly tackling the initial outbreak.
However, experts caution that caution is warranted as more tests need to be conducted before the vaccine can be used. While the results are promising, there have been challenges in developing nasal vaccines.
At least four nasal Covid-19 vaccines are currently undergoing late-stage testing in humans, including one developed by a German team and another by Codagenix.
However, experts warn that respiratory infections have proven to be difficult targets for inhaled vaccines. The US measles vaccine, which uses live attenuated viruses, is an example of successful mucosal immunity.
Another consideration is that people with compromised immune systems may need to exercise caution when using live vaccines due to the risk of infection.
In animal studies, two doses of the vaccine blocked the virus from replicating in the upper airways, producing "sterilizing immunity" and preventing illness. The researchers claim that this is a significant breakthrough as it aims to prevent Covid-19 before it can cause infection.
The German vaccine takes a new approach by weakening the coronavirus through genetic modification, making it easier for the immune system to recognize and fight it off.
While several nasal vaccines are already in use or nearing completion of clinical trials, more work needs to be done before they can be widely used.
In China and India, nasal vaccines have been rolled out but their effectiveness is still unknown due to a lack of published studies.
The US is struggling with Covid-19, with hundreds of Americans dying daily from the infection. The development of next-generation Covid-19 vaccines that induce mucosal immunity and are long-lived is crucial in halting this progress.
Research suggests that boosting mucosal immunity can prevent Covid-19 before it starts to cause illness. This approach mimics the way firefighters would respond to a fire, quickly tackling the initial outbreak.
However, experts caution that caution is warranted as more tests need to be conducted before the vaccine can be used. While the results are promising, there have been challenges in developing nasal vaccines.
At least four nasal Covid-19 vaccines are currently undergoing late-stage testing in humans, including one developed by a German team and another by Codagenix.
However, experts warn that respiratory infections have proven to be difficult targets for inhaled vaccines. The US measles vaccine, which uses live attenuated viruses, is an example of successful mucosal immunity.
Another consideration is that people with compromised immune systems may need to exercise caution when using live vaccines due to the risk of infection.